Advanced search
Start date

Evaluation of HER-2 expression heterogeneity and antitumor effect of Lapatinibe in canine osteosarcomas

Grant number: 19/24468-8
Support type:Scholarships in Brazil - Master
Effective date (Start): June 01, 2020
Effective date (End): February 28, 2022
Field of knowledge:Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
Principal researcher:Carlos Eduardo Fonseca Alves
Grantee:Mayara Simão Franzoni
Home Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil


r is one of the causes of higher mortality in dogs, and osteosarcoma is a type of bone neoplasia that has a high incidence in this species. Recent research has shown that HER-2, a tyrosine kinase receptor, is expressed in this type of tumor, and is associated with poor survival and chemotherapy resistance, in addition to stimulating cell differentiation, migration, apoptosis and angiogenesis, thus blocking This pathway may prevent cell differentiation and migration, induce neoplastic cell apoptosis and decrease angiogenesis. Currently the treatment of choice for canine osteosarcoma is amputation of the affected limb associated with chemotherapy, usually with doxorubicin. Due to new findings in relation to HER-2, new therapies are under development. Lapatinib is a drug that inhibits phosphorylation of this receptor and will be tested in osteosarcoma cell cultures collected at the Veterinary Hospital of the Faculty of Veterinary Medicine and Animal Husbandry. UNESP de Botucatu, in order to compare its antineoplastic effect with the effect of Doxorubicin, besides characterizing the expression of HER-2 in these samples, since there are few studies with this information regarding osteosarcoma in dogs. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list by writing to: